PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Oracle Unveils Fusion Claw + Expands Agentic Applications: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. ...
2026-09-29T    Banking/Financial Service   Biotechnology   Computer/Electronics 
CAS announces collaboration with Novartis to advance AI-ready reaction informatics
Researchers will gain an integrated synthetic data foundation and an advanced custom search platform to support reaction data discovery and analysis   ...
2026-09-29T    Biotechnology   Computer/Electronics   Medical/Pharmaceuticals 
Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
CALGARY, AB , Sept. 29, 2026 /PRNewswire/ -- Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
HRS-1596 is a phase I-ready GLP-1 /GIP dual receptor agonist for once-weekly oral dosing           Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Natural Field to Showcase Liposomal Delivery Technology and Healthy Aging Nutrition Solutions at Hi Japan 2026
SHANGHAI , Sept. 29, 2026 /PRNewswire/ -- Natural Field, a global nutraceutical ingredient solutions provider, announced its participation in Hi Japan 2026, where the company will present its advanced ...
2026-09-29T    Biotechnology   Health Care/Hospital 
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Regent Pacific (0575.HK)'s Deep Longevity Launches Accruaâ„¢ US Consumer Digital Health and Telehealth Platform
Available Across All 50 US States, Extending Deep Longevity's AI-Powered Ageing Science Directly to Consumers  for a Second Growth Curve ...
2026-09-28T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Open-Source Model Accelerates Global Progress in Medical Video AI
SHANGHAI , Sept. 28, 2026 /PRNewswire/ -- Through an open-source model, a public dataset and benchmark, and the MedVidU Challenge, a global research competition, researchers worldwide now share a common ...
2026-09-28T    Biotechnology   Computer/Electronics   Film & Motion Picture   Health Care/Hospital 
Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region
Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader at regional scale ...
2026-09-28T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.